Monoclonal antibodies (mAbs) represent a major breakthrough in biomedical science, including providing precise and versatile tools for cancer research. In cancer, these laboratory-engineered molecules are designed to selectively bind to specific targets, enabling researchers to investigate the complex mechanisms behind tumour formation, growth, and progression. Their high specificity and reproducibility have made them indispensable for advancing our understanding of cancer cell biology. Beyond their research applications, mAbs play a critical role in oncology, contributing to accurate cancer diagnosis and the development of targeted therapies that improve patient treatment and outcomes.
The Monoclonal Antibodies Unit at CNIO specialises in the generation of mAbs utilising hybridoma technology, especially in the production of high-quality antibodies in mice and rats. We are specialised in mAb characterisation and validation to ensure optimal specificity, sensitivity, and performance of the mAbs in different applications (immunohistochemistry, flow cytometry, Western blotting, and immunofluorescence). We also offer medium-scale mAb production to support advanced research applications. Additionally, the Unit performs Mycoplasma testing for the cell culture facility and generation of recombinant antibodies.
Open Access